RHYTHM PHARMACEUTICALS, INC. (RYTM) Latest Filing Signal
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for RHYTHM PHARMACEUTICALS, INC.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, RHYTHM PHARMACEUTICALS, INC.'s filing signal
turned positive.
earningsVibe SuperAnalyst™ Verdict:
TURNED POSITIVE
Signal Performance — Stock Price Since Filing
30-Day Change
-21.23%
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Continuing Positive
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Continuing Positive
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does RHYTHM PHARMACEUTICALS, INC. actually do?
Answer:
Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on developing and commercializing precision medicines for rare neuroendocrine diseases, primarily targeting melanocortin-4 receptor (MC4R) pathway diseases. Its lead asset, IMCIVREE (setmelanotide), is the first therapy approved in the U.S., EU, UK, and Canada for certain rare MC4R pathway diseases, including Bardet-Biedl syndrome (BBS) and obesity due to POMC, PCSK1, or LEPR deficiencies. The company is also advancing two earlier-stage MC4R agonists, bivamelagon (oral) and RM-718 (weekly subcutaneous), and is exploring therapies for congenital hyperinsulinism (CHI). Rhythm Pharmaceuticals is seeking regulatory approval for IMCIVREE in acquired hypothalamic obesity, with anticipated decisions in 2026. The company leverages a large DNA database to advance its understanding and treatment of these rare genetic diseases.
Question:
What are RHYTHM PHARMACEUTICALS, INC.'s revenue drivers?
Answer:
Revenue is primarily driven by product sales of IMCIVREE in its approved indications. The company also generates revenue from license agreements.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required